KALA BIO, Inc. (NASDAQ:KALA) Director Mark T. Iwicki Sells 13,227 Shares

by · The Markets Daily

KALA BIO, Inc. (NASDAQ:KALA – Get Free Report) Director Mark T. Iwicki sold 13,227 shares of the firm’s stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $4.01, for a total value of $53,040.27. Following the completion of the transaction, the director now owns 258,433 shares in the company, valued at $1,036,316.33. This represents a 4.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

KALA BIO Price Performance

Shares of KALA stock opened at $5.26 on Friday. The company has a quick ratio of 1.99, a current ratio of 1.99 and a debt-to-equity ratio of 3.19. KALA BIO, Inc. has a 12-month low of $2.92 and a 12-month high of $11.20. The firm has a fifty day moving average of $3.86 and a 200-day moving average of $5.77. The firm has a market capitalization of $33.93 million, a price-to-earnings ratio of -0.64 and a beta of -1.98.

KALA BIO (NASDAQ:KALA – Get Free Report) last posted its earnings results on Friday, March 28th. The company reported ($1.74) earnings per share for the quarter, topping the consensus estimate of ($2.28) by $0.54. On average, equities research analysts forecast that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Institutional Investors Weigh In On KALA BIO

Several large investors have recently modified their holdings of the business. AIGH Capital Management LLC bought a new position in shares of KALA BIO during the 4th quarter valued at about $842,000. Geode Capital Management LLC raised its holdings in KALA BIO by 28.4% during the 4th quarter. Geode Capital Management LLC now owns 47,642 shares of the company’s stock worth $331,000 after buying an additional 10,526 shares during the period. SR One Capital Management LP lifted its stake in KALA BIO by 35.0% in the fourth quarter. SR One Capital Management LP now owns 598,940 shares of the company’s stock valued at $4,157,000 after buying an additional 155,279 shares in the last quarter. Silverarc Capital Management LLC bought a new position in KALA BIO in the fourth quarter valued at approximately $1,604,000. Finally, Baker BROS. Advisors LP boosted its holdings in shares of KALA BIO by 34.8% in the fourth quarter. Baker BROS. Advisors LP now owns 1,201,894 shares of the company’s stock valued at $8,341,000 after buying an additional 310,559 shares during the period. 24.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

KALA has been the topic of several analyst reports. HC Wainwright cut their target price on KALA BIO from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, May 23rd. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of KALA BIO in a research report on Monday, June 2nd.

Check Out Our Latest Report on KALA

About KALA BIO

(Get Free Report)

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.

See Also